Depomed (DEPO)

[surf1944]

8:04AM DepoMed announces publication of Phase 3 data from Gralise Clinical Trial; says 'This difference from placebo was statistically significant' (DEPO) 5.59 : Co announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN). The results showed that patients treated with Gralise experienced a significant reduction (- 2.12) in their average daily pain intensity compared with placebo treated patients (-1.63; P=0.013). This difference from placebo was statistically significant after one week and continued to be superior through the duration of the study.